These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32639666)

  • 1. Non-vitamin K oral anticoagulants in hypertrophic cardiomyopathy patients undergoing catheter ablation of atrial fibrillation.
    Creta A; Hunter RJ; Earley MJ; Finlay M; Dhinoja M; Sporton S; Chow A; Mohiddin SA; Boveda S; Adragao P; Jebberi Z; Matos D; Schilling RJ; Lambiase PD; Providência R
    J Cardiovasc Electrophysiol; 2020 Oct; 31(10):2626-2631. PubMed ID: 32639666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis.
    Ge Z; Faggioni M; Baber U; Sartori S; Sorrentino S; Farhan S; Chandrasekhar J; Vogel B; Qadeer A; Halperin J; Reddy V; Dukkipati S; Dangas G; Mehran R
    Cardiovasc Ther; 2018 Oct; 36(5):e12457. PubMed ID: 29971964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Nationwide Cohort Study.
    Jung H; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
    Chest; 2019 Feb; 155(2):354-363. PubMed ID: 30472021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy with non-valvular atrial fibrillation.
    Lin Y; Xiong H; Su J; Lin J; Zhou Q; Lin M; Zhao W; Peng F
    Heart Vessels; 2022 Jul; 37(7):1224-1231. PubMed ID: 35041061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation.
    Dominguez F; Climent V; Zorio E; Ripoll-Vera T; Salazar-Mendiguchía J; García-Pinilla JM; Urbano-Moral JA; Fernández-Fernández X; Lopez-Cuenca D; Ajo-Ferrer R; Sanz-Sanchez J; Gomez-Perez Y; López-Garrido MA; Barriales-Villa R; Gimeno JR; Garcia-Pavia P
    Int J Cardiol; 2017 Dec; 248():232-238. PubMed ID: 28811092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
    Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interrupted or Uninterrupted Oral Anticoagulants in Patients Undergoing Atrial Fibrillation Ablation.
    Yang P; Wang C; Ye Y; Huang T; Yang S; Shen W; Xu G; Wu Q
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):371-381. PubMed ID: 32232617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
    Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
    Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation.
    Cardoso R; Knijnik L; Bhonsale A; Miller J; Nasi G; Rivera M; Blumer V; Calkins H
    Heart Rhythm; 2018 Jan; 15(1):107-115. PubMed ID: 28917562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
    Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and hypertrophic cardiomyopathy].
    Liu YY; Du X; He L; Hu R; Ning M; Lyu J; Dong JZ; Ma CS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Jan; 50(1):62-67. PubMed ID: 35045616
    [No Abstract]   [Full Text] [Related]  

  • 13. Minimally interrupted novel oral anticoagulant versus uninterrupted vitamin K antagonist during atrial fibrillation ablation.
    De Heide J; Vroegh CJ; Bhagwandien RE; Wijchers SA; Szili-Torok T; Zijlstra F; Lenzen MJ; Yap SC
    J Interv Card Electrophysiol; 2018 Dec; 53(3):341-346. PubMed ID: 30074120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis.
    Zhou Y; He W; Zhou Y; Zhu W
    J Thromb Thrombolysis; 2020 Aug; 50(2):311-317. PubMed ID: 31792707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials.
    Cardoso R; Willems S; Gerstenfeld EP; Verma A; Schilling R; Hohnloser SH; Okumura K; Nordaby M; Brouwer MA; Calkins H
    Clin Cardiol; 2019 Jan; 42(1):198-205. PubMed ID: 30460702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation.
    Gunawardene M; Willems S; Schäffer B; Moser J; Akbulak RÖ; Jularic M; Eickholt C; Nührich J; Meyer C; Kuklik P; Sehner S; Czerner V; Hoffmann BA
    Clin Res Cardiol; 2017 Jan; 106(1):38-48. PubMed ID: 27435077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis.
    Santarpia G; De Rosa S; Polimeni A; Giampà S; Micieli M; Curcio A; Indolfi C
    PLoS One; 2015; 10(5):e0126512. PubMed ID: 25974377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of the safety and efficacy of using minimally interrupted novel oral anticoagulants in patients undergoing catheter ablation for atrial fibrillation.
    Mao YJ; Wang H; Huang PF
    J Interv Card Electrophysiol; 2021 Apr; 60(3):407-417. PubMed ID: 32361948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies.
    Brunetti ND; Tricarico L; Tilz RR; Heeger CH; De Gennaro L; Correale M; Ieva R; Di Biase M; Rillig A; Metzner A; Santoro F
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):209-214. PubMed ID: 32080786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of randomized controlled trials of uninterrupted periprocedural anticoagulation strategy in patients undergoing atrial fibrillation catheter ablation.
    Zhao Y; Lu Y; Qin Y
    Int J Cardiol; 2018 Nov; 270():167-171. PubMed ID: 29903520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.